Search

Background: Breast conserving surgery (BCS) and its following radiotherapy is an accepted therapeutic method for patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Objectives: The aim of this study was to investigate the effect of intraoperative electron radiotherapy on women with breast cancer (invasive lobular and ductal carcinoma). Methods: Between August 2013 and September 2017, 968 patients, who were referred to Cancer Research Center, Shahid Beheshti University of Medical Sciences with invasive breast cancer, were treated with breast-conserving surgery and radiotherapy. Of those, 426 patients received a tumor bed boost with intraoperative electron radiotherapy (IOERT) during lumpectomy (58 patients with pure invasive lobular carcinoma, 239 patients with pure invasive ductal carcinoma, and 129 patients with other diagnoses). 542 patients received a tumor bed boost with conventional external beam radiotherapy post lumpectomy (24 patients with pure invasive lobular carcinoma, 418 patients with pure invasive ductal carcinoma, and 100 patients with other diagnoses). The patients were followed up to 49 months. A comprehensive list of clinical and pathologic features was evaluated for all patients. We retrospectively analyzed outcomes of breast cancer treated with boost intraoperative electron radiotherapy (pure ILC and IDC groups) and in other group treated with boost conventional external beam radiotherapy (pure ILC group). Results: None of the ILC patients had recurrence in the two groups. The four-year survival rate for ILC patients was 100%, but in the IDC group the survival rate was 97%. Survival analyses showed patients with IDC had a higher risk of ipsilateral breast tumor recurrence (IBTR) and metastasis. Conclusions: Overall, the rates of IBTR and metastasis in the ILC boost IOERT group were significantly low. This finding suggests that IOERT technique deployment in ILC had no inferiority compared with the control group. [ABSTRACT FROM AUTHOR]

Background: Breast conserving surgery and its following radiotherapy is an accepted therapeutic method for patients with invasive lobular carcinoma (ILC). Objectives:We compared clinical outcomes of women diagnosed with ILC or invasive ductal carcinoma (IDC) treated with intraoperative electron radiotherapy (IOERT) boost dose and external beam radiotherapy (EBRT) as whole breast irradiation (WBI) versus EBRT as WBI. Methods: In this retrospective study including 632 patients, who were referred to cancer research center of Shahid Beheshti University from August 2013 to September 2017 and received IORT, after breast-conserving surgery, we compared prognostic factors and ipsilateral breast recurrence (IBR) and distant recurrence (metastasis); 426 patients received a tumor bed boost with IOERT during lumpectomy, 58 patients were pure invasive lobular carcinoma, and 239 patients were pure invasive ductal carcinoma. The patient followed-up to 49 months. We retrospectively analyzed the factors associated with interfering to effects of IOERT with boost dose in the patient with breast cancer. Results: At 4 years, there were 2 cases ipsilateral breast recurrence in the IDC boost IOERT group and 0 cases ILC boost group and there were 5 cases distance or metastatic breast recurrence in the IDC boost IOERT group, and 0 case ILC boost group. Conclusions: Overall, the rates of local recurrence and distant recurrence (metastasis) in the ILC boost IOERT group were signifi- cantly low and compared to the second group, they were not inferior. [ABSTRACT FROM AUTHOR]

Background: Recognizing complications, survival rates, and contributing factors would result in better diseases control in patients with thyroid cancer under thyroidectomy. Accordingly, this study was performed to determine the overall survival and complications in patients with thyroid cancer under thyroidectomy procedure. Methods: In this retrospective, 100 patients with thyroid cancer under thyroidectomy, who were admitted in the affiliated centers of cancer research centers at Shahid Beheshti University of Medical Sciences in recent 5 years from summer 2011 to summer 2016, were enrolled. Data collection was done by census sampling and the required data were collected via existing medical documents and were recorded by checklist from April 2016 to February 2017. Results: Thyroidectomy was total in 97% of the patients, and 3 were under subtotal thyroidectomy (two patients had anaplastic and 1 had micro papillary carcinoma). Twenty-four patients (24%) had some side effects, including no permanent nerve injury but transient nerve injury (Hoarseness) (14%), organ pressure due to hematoma (4%) and tracheal rupture (1%), and transient hypocalcaemia (5%). The recurrence and death were seen in 5% and 3%. The recurrence was related to side effects, but it was not related to death (P > 0.05). Conclusions: We studied overall survival and complications of thyroidectomy in 100 patients with thyroid cancer from summer 2011 to summer 2016 and compared them with statistics on the articles. Thyroidectomy completion is an important procedure in the treatment of a malignant thyroid tumor because of the high rate of contralateral involvement (23.8%). It is a procedure with zero mortality and very low complication rate, not bearing relevant risks. Totally, according to the obtained results in current study, it maybe concluded that thyroidectomy complications are seen in 1 out of 20 patients, especially neck hematoma (4%) and tracheal rupture (1%). The survival in current study is good. [ABSTRACT FROM AUTHOR]

Background: Breast cancer treatment success depends upon prolonging survival with effective treatment, and constant monitoring of recurrence. Survival rate can well be improved by better understanding of prognostic factors, preventive measures, and effective treatments together with follow-up and post-treatment care. Objectives: This study is aimed to know prognostic factors effective in recurrence and death in Iranian breast cancer patients. Methods: This is a retrospective study conducted by reviewing data acquired from 1604 female breast cancer patients who were admitted to Cancer Research Center at Shahid Beheshti University of Medical Sciences between October, 1982 and March, 2014. During the follow-up, after diagnosis, 313 patients experienced recurrence then were classified into two groups: early recurrence, less than 1 year and late recurrence after 5 years. We analyzed prognostic factors of recurrence in each groups and evaluated effective factors of death in this patients. Results: Median age of patients at diagnosis was 50 years. Median follow up time was 4.33 years (range: 0.005-24.9 years). Of these patients, 210 (67.09 %) and 76 (24.28%), developed distant and loco -regional recurrence. Among 313 patients, 62 (21/60%) and 69 (24/04%) had early and late recurrence. In the univariate analysis, tumor grade, stage of disease, ER and PR status, axillary lymph node involvement and lymph vascular invasion were the prognostic factors affecting recurrence in patients, but in the multivariate analysis, ER/PR status was the most important independent prognostic factor affecting the early recurrence and stage of disease were prognostic factors in late recurrence. In all of the recurrent patients, 56.86% (178 individuals) survived and 43.13% (135 individuals) died at the end of follow-up period. The most important factors of death were histologic grade, disease free survival time, site of recurrence and age of disease. Conclusions: Biologic marker, estrogen and progesterone receptors status, had most influence in early recurrence, unlike late recurrence, stage of disease had a more important role. However, lymph vascular invasion has been an effective factor either in early or late recurrence. As a result of studying effective factors in death of these patients, recurrence site, DFS, pathologic grade and patients' age at the time of recurrence came to be effective. Knowing more about affecting factors on recurrence and the death of patients with recurrence, one can try to enhance survival and quality of life in patients by adopting more effective treatments. [ABSTRACT FROM AUTHOR]